Weekly Top News – IBD – April 13, 2020

Xeljanz (tofacitinib) / Pfizer, Marche Polytechnic UniversityODEN: Observational Study To Assess The Effectiveness Of Tofacitinib In Ulcerative Colitis In Clinical Practice In Sweden (clinicaltrials.gov) - Apr 8, 2020 - P; N=120; Not yet recruiting; Sponsor: Pfizer

spesolimab (BI 655130) / Boehringer IngelheimBI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis (clinicaltrials.gov) - Apr 8, 2020 - P2/3; N=98; Active, not recruiting; Sponsor: Boehringer Ingelheim; Recruiting --> Active, not recruiting; N=550 --> 98; Trial completion date: May 2022 --> Aug 2020; Trial primary completion date: May 2022 --> May 2020

ontamalimab (SHP647) / TakedaFIGARO UC 302: Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - Apr 6, 2020 - P3; N=740; Recruiting; Sponsor: Shire; Trial completion date: Nov 2020 --> Jul 2024; Trial primary completion date: Aug 2020 --> Jul 2024

ontamalimab (SHP647) / TakedaFIGARO UC 301: Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - Apr 6, 2020 - P3; N=740; Recruiting; Sponsor: Shire; Trial completion date: Nov 2020 --> Jul 2024; Trial primary completion date: Aug 2020 --> Jul 2024

ontamalimab (SHP647) / TakedaFIGARO UC 303: An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - Apr 6, 2020 - P3; N=696; Recruiting; Sponsor: Shire; Trial completion date: Nov 2021 --> Jun 2024; Trial primary completion date: Aug 2021 --> Jun 2024